T1	And 32 36	with
E1	And:T1 Arg:T30 Arg2:E4
T2	Procedure 37 43	biopsy
E2	Procedure:T2 Name:T31
T3	Modifier 51 90	metastatic cervical nodal squamous cell
E3	Modifier:T3 Modifies:T32
T4	Condition 91 100	carcinoma
E4	Condition:T4 Name:T32
T5	Procedure 106 108	CT
E5	Procedure:T5 Name:T33
T6	Modifier 116 120	neck
E6	Modifier:T6 Modifies:T33
T7	And 121 125	with
E7	And:T7 Arg:E6 Arg2:E30
T9	Eq-Comparison 215 222	Planned
E9	Eq-Comparison:T9 Temporal-Period:T34
T11	Procedure 248 266	PET CT examination
E11	Procedure:T11 Name:T35 Temporality:E9
T12	Eq-Comparison 272 279	Planned
E12	Eq-Comparison:T12 Temporal-Period:T36
T13	Procedure 292 301	care exam
E13	Procedure:T13 Name:T60 Temporality:E12
T14	Procedure 308 318	anesthesia
E14	Procedure:T14 Name:T37
T15	Procedure 324 353	oropharyngeal surgical biopsy
E15	Procedure:T15 Name:T38
T16	Condition 379 387	Pregnant
E16	Condition:T16 Name:T39
T17	Allergy 405 412	allergy
E17	Allergy:T17 Name:E18 Name2:E19 Name3:E22
T18	Drug 416 419	FDG
E18	Drug:T18 Name:T41
T19	Drug 421 433	fluciclovine
E19	Drug:T19 Name:T42
T20	Or 435 437	or
E20	Or:T20 Arg:E19 Arg2:E22
T22	Drug 451 466	contrast agents
E22	Drug:T22 Name:T45
T23	Condition 479 496	renal dysfunction
E23	Condition:T23 Name:T47 Severity:T46
T24	Observation 498 522	glomerular filtrate rate
E24	Observation:T24 Name:T48 Temporality:E25 Eq-Comparison:E26
T25	Eq-Comparison 524 538	within 30 days
E25	Eq-Comparison:T25 Operator:T49 Value:T50 Temporal-Unit:T51
T26	Eq-Comparison 540 552	less than 30
E26	Eq-Comparison:T26 Operator:T52 Value:T53
T27	Condition 559 593	Inability to tolerate lying supine
E27	Condition:T27 Name:T54 Duration:E29
T29	Eq-Comparison 621 633	up to 1 hour
E29	Eq-Comparison:T29 Value:T55 Temporal-Unit:T56 Operator:T28
T30	Life-Stage-And-Gender 25 31	Adults
A1	Life-Stage-And-Gender-Type T30 adult
T31	Procedure-Name 37 43	biopsy
T32	Condition-Name 91 100	carcinoma
T33	Procedure-Name 106 108	CT
T34	Eq-Temporal-Period 215 222	Planned
A2	Eq-Temporal-Period-Value T34 future
T35	Procedure-Name 248 266	PET CT examination
T36	Eq-Temporal-Period 272 279	Planned
A3	Eq-Temporal-Period-Value T36 future
T37	Procedure-Name 308 318	anesthesia
T38	Procedure-Name 324 353	oropharyngeal surgical biopsy
T39	Condition-Name 379 387	Pregnant
T40	Life-Stage-And-Gender 388 393	women
A4	Life-Stage-And-Gender-Type T40 female
T41	Drug-Name 416 419	FDG
T42	Drug-Name 421 433	fluciclovine
T45	Drug-Name 451 466	contrast agents
T46	Severity 472 478	Severe
A6	Severity-Value T46 severe
T47	Condition-Name 479 496	renal dysfunction
T48	Observation-Name 498 522	glomerular filtrate rate
A7	Observation-Type-Value T48 lab
T49	Eq-Operator 524 530	within
A8	Eq-Operator-Value T49 LTEQ
T50	Eq-Value 531 533	30
T51	Eq-Temporal-Unit 534 538	days
A9	Eq-Temporal-Unit-Value T51 day
T52	Eq-Operator 540 549	less than
A10	Eq-Operator-Value T52 LT
T53	Eq-Value 550 552	30
T54	Condition-Name 559 593	Inability to tolerate lying supine
T55	Eq-Value 627 628	1
T56	Eq-Temporal-Unit 629 633	hour
A11	Eq-Temporal-Unit-Value T56 hour
R1	Found-By Arg1:E4 Arg2:E2	
T57	Modifier 126 134	contrast
E30	Modifier:T57 Modifies:T33
T8	Coreference 202 209	disease
E8	Coreference:T8 Refers-To:E4
T58	Modifier 172 198	primary oropharyngeal site
E31	Modifier:T58 Modifies:E8
T59	Negation 145 148	not
E32	Negation:T59 Negates:E31
R2	Treatment-For Arg1:E5 Arg2:E8	
T10	Modifier 240 247	18F-FDG
E10	Modifier:T10 Modifies:T35
T60	Procedure-Name 292 301	care exam
R3	Using Arg1:E13 Arg2:E14	
T61	And 319 323	with
E33	And:T61 Arg:E14 Arg2:E15
R4	Using Arg1:E13 Arg2:E15	
R5	If-Then Arg1:E16 Arg2:T40	
T21	Modifier 438 450	iodine-based
E21	Modifier:T21 Modifies:T45
R6	Equivalent-To Arg1:E24 Arg2:E23	
T28	Eq-Operator 621 626	up to
A5	Eq-Operator-Value T28 LTEQ
T43	Modifier 595 616	relatively motionless
E28	Modifier:T43 Modifies:T54
